Cargando…
Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features
INTRODUCTION: The distinction between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IPM) holds clinical significance in staging, therapeutic intervention, and prognosis assessment for multiple lung cancer. Lineage tracing by clinicopathologic features alone remains a clinical ch...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548834/ https://www.ncbi.nlm.nih.gov/pubmed/37799479 http://dx.doi.org/10.3389/fonc.2023.1237308 |
_version_ | 1785115360870006784 |
---|---|
author | Song, Yijun Zhou, Jiebai Zhao, Xiaotian Zhang, Yong Xu, Xiaobo Zhang, Donghui Pang, Jiaohui Bao, Hairong Ji, Yuan Zhan, Mengna Wang, Yulin Ou, Qiuxiang Hu, Jie |
author_facet | Song, Yijun Zhou, Jiebai Zhao, Xiaotian Zhang, Yong Xu, Xiaobo Zhang, Donghui Pang, Jiaohui Bao, Hairong Ji, Yuan Zhan, Mengna Wang, Yulin Ou, Qiuxiang Hu, Jie |
author_sort | Song, Yijun |
collection | PubMed |
description | INTRODUCTION: The distinction between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IPM) holds clinical significance in staging, therapeutic intervention, and prognosis assessment for multiple lung cancer. Lineage tracing by clinicopathologic features alone remains a clinical challenge; thus, we aimed to develop a multi-omics analysis method delineating spatiotemporal heterogeneity based on tumor genomic profiling. METHODS: Between 2012 and 2022, 11 specimens were collected from two patients diagnosed with multiple lung cancer (LU1 and LU2) with synchronous/metachronous tumors. A novel multi-omics analysis method based on whole-exome sequencing, transcriptome sequencing (RNA-Seq), and tumor neoantigen prediction was developed to define the lineage. Traditional clinicopathologic reviews and an imaging-based algorithm were performed to verify the results. RESULTS: Seven tissue biopsies were collected from LU1. The multi-omics analysis method demonstrated that three synchronous tumors observed in 2018 (LU1B/C/D) had strong molecular heterogeneity, various RNA expression and immune microenvironment characteristics, and unique neoantigens. These results suggested that LU1B, LU1C, and LU1D were MPLC, consistent with traditional lineage tracing approaches. The high mutational landscape similarity score (75.1%), similar RNA expression features, and considerable shared neoantigens (n = 241) revealed the IPM relationship between LU1F and LU1G which were two samples detected simultaneously in 2021. Although the multi-omics analysis method aligned with the imaging-based algorithm, pathology and clinicopathologic approaches suggested MPLC owing to different histological types of LU1F/G. Moreover, controversial lineage or misclassification of LU2’s synchronous/metachronous samples (LU2B/D and LU2C/E) traced by traditional approaches might be corrected by the multi-omics analysis method. Spatiotemporal heterogeneity profiled by the multi-omics analysis method suggested that LU2D possibly had the same lineage as LU2B (similarity score, 12.9%; shared neoantigens, n = 71); gefitinib treatment and EGFR, TP53, and RB1 mutations suggested the possibility that LU2E might result from histology transformation of LU2C despite the lack of LU2C biopsy and its histology. By contrast, histological interpretation was indeterminate for LU2D, and LU2E was defined as a primary or progression lesion of LU2C by histological, clinicopathologic, or imaging-based approaches. CONCLUSION: This novel multi-omics analysis method improves the accuracy of lineage tracing by tracking the spatiotemporal heterogeneity of serial samples. Further validation is required for its clinical application in accurate diagnosis, disease management, and improving prognosis. |
format | Online Article Text |
id | pubmed-10548834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105488342023-10-05 Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features Song, Yijun Zhou, Jiebai Zhao, Xiaotian Zhang, Yong Xu, Xiaobo Zhang, Donghui Pang, Jiaohui Bao, Hairong Ji, Yuan Zhan, Mengna Wang, Yulin Ou, Qiuxiang Hu, Jie Front Oncol Oncology INTRODUCTION: The distinction between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IPM) holds clinical significance in staging, therapeutic intervention, and prognosis assessment for multiple lung cancer. Lineage tracing by clinicopathologic features alone remains a clinical challenge; thus, we aimed to develop a multi-omics analysis method delineating spatiotemporal heterogeneity based on tumor genomic profiling. METHODS: Between 2012 and 2022, 11 specimens were collected from two patients diagnosed with multiple lung cancer (LU1 and LU2) with synchronous/metachronous tumors. A novel multi-omics analysis method based on whole-exome sequencing, transcriptome sequencing (RNA-Seq), and tumor neoantigen prediction was developed to define the lineage. Traditional clinicopathologic reviews and an imaging-based algorithm were performed to verify the results. RESULTS: Seven tissue biopsies were collected from LU1. The multi-omics analysis method demonstrated that three synchronous tumors observed in 2018 (LU1B/C/D) had strong molecular heterogeneity, various RNA expression and immune microenvironment characteristics, and unique neoantigens. These results suggested that LU1B, LU1C, and LU1D were MPLC, consistent with traditional lineage tracing approaches. The high mutational landscape similarity score (75.1%), similar RNA expression features, and considerable shared neoantigens (n = 241) revealed the IPM relationship between LU1F and LU1G which were two samples detected simultaneously in 2021. Although the multi-omics analysis method aligned with the imaging-based algorithm, pathology and clinicopathologic approaches suggested MPLC owing to different histological types of LU1F/G. Moreover, controversial lineage or misclassification of LU2’s synchronous/metachronous samples (LU2B/D and LU2C/E) traced by traditional approaches might be corrected by the multi-omics analysis method. Spatiotemporal heterogeneity profiled by the multi-omics analysis method suggested that LU2D possibly had the same lineage as LU2B (similarity score, 12.9%; shared neoantigens, n = 71); gefitinib treatment and EGFR, TP53, and RB1 mutations suggested the possibility that LU2E might result from histology transformation of LU2C despite the lack of LU2C biopsy and its histology. By contrast, histological interpretation was indeterminate for LU2D, and LU2E was defined as a primary or progression lesion of LU2C by histological, clinicopathologic, or imaging-based approaches. CONCLUSION: This novel multi-omics analysis method improves the accuracy of lineage tracing by tracking the spatiotemporal heterogeneity of serial samples. Further validation is required for its clinical application in accurate diagnosis, disease management, and improving prognosis. Frontiers Media S.A. 2023-09-14 /pmc/articles/PMC10548834/ /pubmed/37799479 http://dx.doi.org/10.3389/fonc.2023.1237308 Text en Copyright © 2023 Song, Zhou, Zhao, Zhang, Xu, Zhang, Pang, Bao, Ji, Zhan, Wang, Ou and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Song, Yijun Zhou, Jiebai Zhao, Xiaotian Zhang, Yong Xu, Xiaobo Zhang, Donghui Pang, Jiaohui Bao, Hairong Ji, Yuan Zhan, Mengna Wang, Yulin Ou, Qiuxiang Hu, Jie Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
title | Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
title_full | Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
title_fullStr | Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
title_full_unstemmed | Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
title_short | Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
title_sort | lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548834/ https://www.ncbi.nlm.nih.gov/pubmed/37799479 http://dx.doi.org/10.3389/fonc.2023.1237308 |
work_keys_str_mv | AT songyijun lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT zhoujiebai lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT zhaoxiaotian lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT zhangyong lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT xuxiaobo lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT zhangdonghui lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT pangjiaohui lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT baohairong lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT jiyuan lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT zhanmengna lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT wangyulin lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT ouqiuxiang lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures AT hujie lineagetracingformultiplelungcancerbyspatiotemporalheterogeneityusingamultiomicsanalysismethodintegratinggenomictranscriptomicandimmunerelatedfeatures |